These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 2584067)
1. [Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck]. Koch T; Eiffert H; Spindler MB HNO; 1989 Nov; 37(11):454-9. PubMed ID: 2584067 [TBL] [Abstract][Full Text] [Related]
2. [Squamous cell carcinoma antigen. Current clinical value of a new tumor marker in head and neck cancer; preliminary results of a prospective study after 12 months]. Clasen B; Roettger D; Senekowitsch R; Menz E Laryngol Rhinol Otol (Stuttg); 1988 Aug; 67(8):420-5. PubMed ID: 3210877 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis of recurrences of head and neck carcinoma with the tumor marker SSC-antigen]. Arlt A; Luckhaupt H; Hildmann H Laryngorhinootologie; 2000 Apr; 79(4):207-12. PubMed ID: 10838684 [TBL] [Abstract][Full Text] [Related]
4. [The SCC antigen is not a reliable tumor marker in the ENT area. Value of squamous cell carcinoma antigen in diagnosis and follow-up of squamous epithelial carcinoma in the head-neck area. Results of a retrospective study over 6 years]. Gotschuli A; Anderhuber W; Danninger R; Habermann W Laryngorhinootologie; 1998 Mar; 77(3):165-7. PubMed ID: 9577824 [TBL] [Abstract][Full Text] [Related]
5. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093 [TBL] [Abstract][Full Text] [Related]
6. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Eibling DE; Johnson JT; Wagner RL; Su S Laryngoscope; 1989 Feb; 99(2):117-24. PubMed ID: 2913421 [TBL] [Abstract][Full Text] [Related]
7. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)]. Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197 [TBL] [Abstract][Full Text] [Related]
8. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers]. Geyer H; Schwörer D; Pfleiderer A Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888 [TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of tumor markers in head and neck squamous cell carcinomas]. Yoneda K; Hirota J; Yamamoto T; Ueta E; Osaki T Gan No Rinsho; 1990 Mar; 36(4):458-64. PubMed ID: 2181163 [TBL] [Abstract][Full Text] [Related]
10. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Gadducci A; Tana R; Cosio S; Genazzani AR Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182 [TBL] [Abstract][Full Text] [Related]
11. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC). Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591 [TBL] [Abstract][Full Text] [Related]
12. The clinical value of squamous cell carcinoma antigen in patients irradiated for locally advanced cancer of the head and neck. Micke O; Bruns F; Schäfer U; Horst E; Büntzel J; Willich N Anticancer Res; 2003; 23(2A):907-11. PubMed ID: 12820321 [TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778 [TBL] [Abstract][Full Text] [Related]
14. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix]. Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H Geburtshilfe Frauenheilkd; 1989 Jul; 49(7):625-9. PubMed ID: 2777050 [TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinoma antigen in oral squamous cell carcinomas. Nagumo K; Okada N; Takagi M; Yamamoto H; Amagasa T; Fujibayashi T Bull Tokyo Med Dent Univ; 1990 Jun; 37(1-2):27-34. PubMed ID: 2225283 [TBL] [Abstract][Full Text] [Related]
16. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma]. Ychou M; Khemissa-Akouz F; Kramar A; Senesse P; Grenier J Bull Cancer; 2001 Oct; 88(10):1023-7. PubMed ID: 11713038 [TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy. Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861 [TBL] [Abstract][Full Text] [Related]
18. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026 [TBL] [Abstract][Full Text] [Related]
20. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]